Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-9839 + SHR-A2009
- Development stage
- Unknown
- Lead developer
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-9839 + SHR-A2009 is a combination therapy under clinical investigation for advanced solid tumors. SHR-9839 is a humanized antibody drug designed to block two key signaling pathways involved in tumor progression. SHR-A2009 is an antibody-drug conjugate (ADC) targeting the HER3 receptor, equipped with a cleavable linker and a topoisomerase I inhibitor payload. After binding HER3 on tumor cell surfaces, SHR-A2009 is internalized and delivers its cytotoxic payload to induce tumor cell death. This combination is developed for anti-tumor activity in patients with advanced solid tumors, and is being studied particularly in the context of combination regimens for enhanced efficacy and safety[1][2][3][7].
- Other names
- SHR-9839 + SHR-A2009
02
Targets
TOP1 (DNA Topoisomerase I)EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on SHR-9839 + SHR-A2009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-9839 + SHR-A2009.